Education
About Us
Working with TipRanks
Follow Us
HBM Holdings Ltd. (HK:2142)
:2142
RESEARCH TOOLSreports
2142 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.06 - HK$10.00
Previous CloseN/A
Volume9.30M
Average Volume (3M)10.86M
Market Cap
HK$6.51B
Enterprise ValueHK$829.32M
Total Cash (Recent Filing)HK$167.22M
Total Debt (Recent Filing)$61.34M
Price to Earnings (P/E)268.6
Beta1.48
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding846,774,100
10 Day Avg. Volume12,268,230
30 Day Avg. Volume10,856,176
Financial Highlights & Ratios
PEG Ratio-3.84
Price to Book (P/B)7.48
Price to Sales (P/S)0.00
P/FCF Ratio22.26
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit24.67
Enterprise Value/Ebitda-939.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HBM Holdings Ltd. News
PremiumCompany Announcements
HBM Holdings Secures Patent Victory, Strengthening Biotech Innovations
PremiumCompany Announcements
HBM Holdings Announces Successful AGM Resolutions
PremiumCompany Announcements
HBM Holdings Appoints Dr. Ian Yi Liu as Joint Company Secretary
PremiumCompany Announcements
HBM Holdings Announces Change in Company Secretary
PremiumCompany Announcements
HBM Holdings to Present MesoC2 Clinical Study at ASCO 2025
PremiumCompany Announcements
HBM Holdings Ltd. Grants Share Options to EmployeesOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.21%
Mutual Funds
― Other Institutional Investors
99.63% Public Companies and
Individual Investors
2142 FAQ
What was HBM Holdings Ltd.’s price range in the past 12 months?
HBM Holdings Ltd. lowest stock price was HK$1.06 and its highest was HK$10.00 in the past 12 months.
What is HBM Holdings Ltd.’s market cap?
HBM Holdings Ltd.’s market cap is HK$6.51B.
When is HBM Holdings Ltd.’s upcoming earnings report date?
HBM Holdings Ltd.’s upcoming earnings report date is Aug 27, 2025 which is in 66 days.
How were HBM Holdings Ltd.’s earnings last quarter?
HBM Holdings Ltd. released its earnings results on Mar 31, 2025. The company reported HK$0.014 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.014.
Is HBM Holdings Ltd. overvalued?
According to Wall Street analysts HBM Holdings Ltd.’s price is currently Overvalued.
Does HBM Holdings Ltd. pay dividends?
HBM Holdings Ltd. does not currently pay dividends.
What is HBM Holdings Ltd.’s EPS estimate?
HBM Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HBM Holdings Ltd. have?
HBM Holdings Ltd. has 846,774,100 shares outstanding.
What happened to HBM Holdings Ltd.’s price movement after its last earnings report?
HBM Holdings Ltd. reported an EPS of HK$0.014 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.961%.
Which hedge fund is a major shareholder of HBM Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2142
HBM Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
494.65%
12-Months-Change
Fundamentals
Return on Equity
2.28%
Trailing 12-Months
Asset Growth
-6.38%
Trailing 12-Months
Company Description
HBM Holdings Ltd.
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
Abbisko Cayman Limited
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―